{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pulmonary-embolism/prescribing-information/oral-anticoagulants/","result":{"pageContext":{"chapter":{"id":"f367e7b5-6b1b-5f42-9d57-a8edab35855f","slug":"oral-anticoagulants","fullItemName":"Oral anticoagulants","depth":2,"htmlHeader":"<!-- begin field 0221b4ef-214b-45e9-84ca-ab8e00ae7287 --><h2>Oral anticoagulants</h2><!-- end field 0221b4ef-214b-45e9-84ca-ab8e00ae7287 -->","summary":"","htmlStringContent":"<!-- begin item f6892a1e-8da9-4b25-9efe-ab8e00ae7257 --><!-- begin field ec28521a-4c6b-440f-b605-ab8e00ae7287 --><ul><li>The direct oral anticoagulants (DOACs) licensed for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults are:<ul><li>Apixaban.</li><li>Dabigatran.</li><li>Edoxaban.</li><li>Rivaroxaban.</li></ul></li><li>Warfarin is also licensed for the treatment and prophylaxis of DVT and PE. </li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">NICE, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">NICE, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">NICE, 2015c</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">ABPI, 2018d</a>]</p><!-- end field ec28521a-4c6b-440f-b605-ab8e00ae7287 --><!-- end item f6892a1e-8da9-4b25-9efe-ab8e00ae7257 -->","topic":{"id":"322088c5-226e-5f2b-9fd2-2e2c0678abc1","topicId":"6b233aab-5318-4abb-96fa-1877e917ef2c","topicName":"Pulmonary embolism","slug":"pulmonary-embolism","lastRevised":"Last revised in October 2020","chapters":[{"id":"7d60ce89-0a3c-5336-a5d4-755eb5bfb2cd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"99df9a07-7867-5283-b7c8-4589c8f6e029","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b4da2d8a-f835-512f-b218-660b7fc61806","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c60f44ed-a5f4-566e-8718-a289b4d4e969","slug":"changes","fullItemName":"Changes"},{"id":"42a750f4-f134-55a8-a654-9c23ac2a3bfd","slug":"update","fullItemName":"Update"}]},{"id":"b8001d19-4cf2-5db4-b8b5-f082fbff4fbd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"52656989-9cf4-597c-8118-0fadcb887b21","slug":"goals","fullItemName":"Goals"},{"id":"cdd140ec-bd30-59e9-9777-c921159ea664","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c32413cc-9382-5aaa-b03b-95ed29a1b360","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c1a308a6-aa46-578f-98f1-ed7872474fb4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1629cec2-329a-5273-a313-15a0783d5b22","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d4860e1f-9b8b-5f49-bdb5-fb068af327ab","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9e6802a1-b9c3-5fa9-b632-ef9712c1724b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"588bb6e5-794e-52df-9953-d91254204285","slug":"definition","fullItemName":"Definition"},{"id":"e2fbb90b-8419-52d9-bfd2-a9eab621be3b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ad38abd5-7668-59b3-828a-9edd427dbdd5","slug":"pathophysiology","fullItemName":"Pathophysiology"},{"id":"9b45f610-d957-50a3-9e85-019832acd145","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"8e279dc8-2394-5073-8866-952291c0eee6","slug":"complications","fullItemName":"Complications"},{"id":"8be5980d-145d-5d9c-b255-f057579ce868","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"c07c0850-0c27-58a8-96a8-96051968c076","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1db70c8e-a80c-587a-8e5e-5adf28878587","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"a71fc8ea-c1d7-5be5-a888-41b834fdca93","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f18a5246-939d-51ce-adb5-f6538871345a","fullItemName":"Management","slug":"management","subChapters":[{"id":"42f102a2-ceab-531f-880e-4075895d9c12","slug":"suspected-pulmonary-embolism","fullItemName":"Scenario: Suspected pulmonary embolism"},{"id":"cd66b55b-908e-56dc-811f-db55be20b710","slug":"confirmed-pulmonary-embolism","fullItemName":"Scenario: Confirmed pulmonary embolism"}]},{"id":"6ae8a494-48a2-5d60-b0f8-39dd5e02489b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8b812684-b06c-50e2-86d7-f012b792c674","slug":"parenteral-anticoagulants","fullItemName":"Parenteral anticoagulants"},{"id":"f367e7b5-6b1b-5f42-9d57-a8edab35855f","slug":"oral-anticoagulants","fullItemName":"Oral anticoagulants"}]},{"id":"c1bef62c-2c5a-5588-af53-1a0b4b26d3e3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3941fd8f-10fb-53d4-8dc1-3835ad3ca3e3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"26fc4bf9-2995-5109-9f1e-3ba9ad3dd2dd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f1b2f1f8-81e2-5a3c-b454-2f63f66f6235","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"83fd7f66-6953-54a6-b55f-8d2858a82e97","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bd9e363f-a674-594d-8bb9-8779d385e06a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"20c76427-9b00-5da0-bd68-6486385780f2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"96a22dd0-587f-5051-8263-acea49ba216b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6ae8a494-48a2-5d60-b0f8-39dd5e02489b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"9495abf2-a7d7-5651-a00c-8d594c3884d7","slug":"apixaban","fullItemName":"Apixaban","depth":3,"htmlHeader":"<!-- begin field 9a279655-8700-456f-b511-ab8e00ae86a5 --><h3>What should I be aware of when prescribing apixaban?</h3><!-- end field 9a279655-8700-456f-b511-ab8e00ae86a5 -->","summary":"","htmlStringContent":"<!-- begin item bc8d504b-1eed-4484-8e30-ab8e00ae8675 --><!-- begin field 8248fe74-5196-4598-8c3c-ab8e00ae86a5 --><ul><li>Apixaban should be taken orally.</li><li>The recommended dose of apixaban for the treatment of pulmonary embolism is 10 mg twice daily for 7 days, followed by a maintenance dose of 5 mg twice daily.</li><li>For detailed prescribing information, including contraindications, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/\">Apixaban</a> in the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/\">Anticoagulation - oral</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">ABPI, 2020b</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 8248fe74-5196-4598-8c3c-ab8e00ae86a5 --><!-- end item bc8d504b-1eed-4484-8e30-ab8e00ae8675 -->","subChapters":[]},{"id":"6bfd7196-b915-5b99-8fbf-c784cc3355b3","slug":"rivaroxaban","fullItemName":"Rivaroxaban","depth":3,"htmlHeader":"<!-- begin field 46b649a2-99ae-484d-9c09-ab8e00ae9992 --><h3>What should I be aware of when prescribing rivaroxaban?</h3><!-- end field 46b649a2-99ae-484d-9c09-ab8e00ae9992 -->","summary":"","htmlStringContent":"<!-- begin item 654914f4-ec9c-4087-be56-ab8e00ae9966 --><!-- begin field 90a1a8d1-6f78-4abc-9434-ab8e00ae9992 --><ul><li>Rivaroxaban should be taken orally with food.  </li><li>The recommended dose of rivaroxaban for the treatment of pulmonary embolism is 15 mg twice daily (on days 1–21), followed by a maintenance dose of 20 mg once daily.</li><li>For detailed prescribing information, including contraindications, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/management/rivaroxaban/\">Rivaroxaban</a> in the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/\">Anticoagulation - oral</a>.</li><li>Rivaroxaban is a black triangle drug and is subject to additional monitoring. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">MHRA, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Joint Formulary Committee, 2020</a>] </p><!-- end field 90a1a8d1-6f78-4abc-9434-ab8e00ae9992 --><!-- end item 654914f4-ec9c-4087-be56-ab8e00ae9966 -->","subChapters":[]},{"id":"95d84b1c-4663-582d-89cd-ae9f96088e65","slug":"dabigatran","fullItemName":"Dabigatran","depth":3,"htmlHeader":"<!-- begin field b558bf6a-9a07-43de-ae61-ab8e00aea79b --><h3>What should I be aware of when prescribing dabigatran?</h3><!-- end field b558bf6a-9a07-43de-ae61-ab8e00aea79b -->","summary":"","htmlStringContent":"<!-- begin item d13e57f2-7adb-4eee-b7b7-ab8e00aea74e --><!-- begin field f180800b-abe2-4b1a-9577-ab8e00aea79b --><ul><li>The recommended dose of dabigatran for the treatment of pulmonary embolism (following treatment with a parenteral anticoagulant for at least 5 days) is:<ul><li>150 mg twice daily in people aged 18–74 years.</li><li>110 to 150 mg twice daily in people aged 75–79 years.</li><li>110 mg twice daily in people aged 80 years and over.</li></ul></li><li>For detailed prescribing information, including contraindications, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/management/dabigatran/\">Dabigatran</a> in the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/\">Anticoagulation - oral</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field f180800b-abe2-4b1a-9577-ab8e00aea79b --><!-- end item d13e57f2-7adb-4eee-b7b7-ab8e00aea74e -->","subChapters":[]},{"id":"67f2f247-2bf3-5eab-b718-aaba49739843","slug":"edoxaban","fullItemName":"Edoxaban","depth":3,"htmlHeader":"<!-- begin field e481ba09-135c-46f9-ab7a-ab8e00aeb437 --><h3>What should I be aware of when prescribing edoxaban?</h3><!-- end field e481ba09-135c-46f9-ab7a-ab8e00aeb437 -->","summary":"","htmlStringContent":"<!-- begin item e69141d4-d7d7-4f16-9693-ab8e00aeb410 --><!-- begin field a8a2a66f-488d-4a14-b1cb-ab8e00aeb437 --><ul><li>The recommended dose of edoxaban for the treatment of pulmonary embolism is 60 mg once daily (30 mg once daily in people, with body weight of 61 kg or less) following initial use of parenteral anticoagulant for at least 5 days.</li><li>For detailed prescribing information, including contraindications, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/\">Edoxaban</a> in the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/\">Anticoagulation - oral</a>.</li><li>Edoxaban is a black triangle drug and is subject to additional monitoring. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field a8a2a66f-488d-4a14-b1cb-ab8e00aeb437 --><!-- end item e69141d4-d7d7-4f16-9693-ab8e00aeb410 -->","subChapters":[]},{"id":"4b87a1d9-44d8-5567-8ab1-45f02d793b52","slug":"warfarin","fullItemName":"Warfarin","depth":3,"htmlHeader":"<!-- begin field 852d8082-9291-47a6-8bb8-ab8e00aec07c --><h3>What should I be aware of when prescribing warfarin?</h3><!-- end field 852d8082-9291-47a6-8bb8-ab8e00aec07c -->","summary":"","htmlStringContent":"<!-- begin item 42e844f9-1229-4928-9329-ab8e00aec057 --><!-- begin field a3c40014-da15-43c0-a476-ab8e00aec07c --><ul><li>Warfarin should be started within 24 hours of confirmed pulmonary embolism and is taken orally in combination with a parenteral anticoagulant — low molecular weight heparin (LMWH). <ul><li>The LMHW is started as soon as possible and continued for at least 5 days, or until the international normalised ratio (INR) is 2 or above for at least 24 hours, whichever is longer, and the warfarin continued for at least 3 months.</li></ul></li><li>The typical induction dose of warfarin is 10 mg daily for 2 days, and the daily maintenance dose is usually 3 to 9 mg taken at the same time each day. However, doses should be tailored depending on the person's INR. </li><li>For detailed prescribing information, including contraindications, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/management/warfarin/\">Warfarin</a> in the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/\">Anticoagulation - oral</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Joint Formulary Committee, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">NICE, 2020</a>]</p><!-- end field a3c40014-da15-43c0-a476-ab8e00aec07c --><!-- end item 42e844f9-1229-4928-9329-ab8e00aec057 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}